Iberdomide in combination with dexamethasone and daratumumab or bortezomib in patients with relapsed/refractory multiple myeloma: first results from the CC-220-MM-001 study

Autores: van-de-Donk, N. W. C. J.; Popat, R.; Larsen, J.; Minnema, M. C.; Jagannath, S.; Oriol, A.; Zonder, J. A.; Richardson, P. G.; Rodríguez Otero, Paula; Badros, A. Z.; Stadtmauer, E.; Bringhen, S.; Campagnaro, E.; Siegel, D. S.; Gamberi, B.; Mesa, M. G.; Sonneveld, P.; Nguyen, T. V.; Di-Micco, A.; Sorrell, A.; Chen, M.; Amatangelo, M.; Kueenburg, E.; Lonial, S.